B-intervention	0	6	Mobile
I-intervention	7	13	health
I-intervention	14	17	and
I-intervention	18	28	supervised
I-intervention	29	43	rehabilitation
O	44	50	versus
B-control	51	57	mobile
I-control	58	64	health
I-control	65	70	alone
O	71	73	in
O	74	80	breast
O	81	87	cancer
O	88	97	survivors
O	97	98	:
O	99	109	Randomized
O	110	120	controlled
O	121	126	trial
O	126	127	.

O	128	136	Survival
O	137	142	rates
O	143	145	in
O	146	152	cancer
O	153	156	are
O	157	167	increasing
O	168	181	exponentially
O	181	182	,
O	183	187	with
O	188	189	a
O	190	203	corresponding
O	204	212	increase
O	212	213	/
O	213	222	influence
O	223	225	in
O	226	236	disability
O	236	237	-
O	237	245	adjusted
O	246	250	life
O	250	251	-
O	251	256	years
O	256	257	.

O	258	265	Efforts
O	266	272	should
O	273	275	be
O	276	280	made
O	281	283	to
O	284	291	explore
O	292	295	the
O	296	303	optimal
O	304	311	balance
O	312	319	between
O	320	332	unsupervised
O	332	333	/
O	333	341	distance
O	341	342	-
O	342	347	based
O	348	351	and
O	352	362	supervised
O	362	363	/
O	363	369	onsite
O	370	380	approaches
O	381	383	to
O	384	390	cancer
O	391	395	care
O	395	396	.

O	397	401	This
O	402	407	study
O	408	413	aimed
O	414	416	to
O	417	424	compare
O	425	428	the
O	429	437	clinical
O	438	446	efficacy
O	447	449	of
O	450	453	the
O	454	460	BENECA
O	461	467	mobile
O	468	474	Health
O	475	476	(
O	476	483	mHealth
O	483	484	)
O	485	494	lifestyle
O	495	506	application
O	507	515	combined
O	516	520	with
O	521	522	a
O	523	533	supervised
O	534	548	rehabilitation
O	549	556	program
O	557	558	(
O	558	564	BENECA
O	565	568	and
O	569	579	supervised
O	580	594	rehabilitation
O	594	595	)
O	596	602	versus
O	603	606	the
O	607	613	BENECA
O	614	621	mHealth
O	622	631	lifestyle
O	632	643	application
O	644	649	alone
O	650	652	on
O	653	660	quality
O	661	663	of
O	664	668	life
O	669	670	(
O	670	673	QoL
O	673	674	)
O	675	678	and
O	679	689	functional
O	690	698	outcomes
O	699	701	of
O	702	708	breast
O	709	715	cancer
O	716	725	survivors
O	725	726	.

O	727	731	This
O	732	742	randomized
O	743	753	controlled
O	754	759	trial
O	760	768	included
B-total-participants	769	771	80
B-eligibility	772	781	survivors
I-eligibility	782	784	of
I-eligibility	785	791	breast
I-eligibility	792	798	cancer
I-eligibility	799	808	diagnosed
I-eligibility	809	811	at
I-eligibility	812	817	stage
I-eligibility	818	819	I
I-eligibility	819	820	-
I-eligibility	820	824	IIIA
I-eligibility	824	825	,
I-eligibility	826	829	who
I-eligibility	830	839	completed
I-eligibility	840	848	adjuvant
I-eligibility	849	856	therapy
I-eligibility	857	860	and
I-eligibility	861	865	were
I-eligibility	866	876	overweight
I-eligibility	877	879	or
I-eligibility	880	885	obese
I-eligibility	886	888	at
I-eligibility	889	898	diagnosis
O	898	899	.

O	900	912	Participants
O	913	917	were
O	918	926	randomly
O	927	936	allocated
O	937	938	(
O	938	943	ratio
O	944	945	1
O	945	946	:
O	946	947	1
O	947	948	,
O	949	950	3
O	951	956	waves
O	956	957	)
O	958	960	to
O	961	967	BENECA
O	968	975	mHealth
O	976	979	and
O	980	994	rehabilitation
O	995	998	for
O	999	1006	2months
O	1007	1008	(
O	1008	1009	n
O	1009	1010	=
B-intervention-participants	1010	1012	40
O	1012	1013	)
O	1014	1016	or
O	1017	1023	BENECA
O	1024	1031	mHealth
O	1032	1035	and
O	1036	1041	usual
O	1042	1046	care
O	1047	1048	(
O	1048	1054	BENECA
O	1055	1062	mHealth
O	1063	1068	alone
O	1068	1069	;
O	1070	1071	n
O	1071	1072	=
B-control-participants	1072	1074	40
O	1074	1075	)
O	1075	1076	.

O	1077	1089	Participants
O	1090	1099	completed
O	1100	1101	a
O	1102	1115	questionnaire
O	1116	1118	at
O	1119	1127	baseline
O	1128	1129	(
O	1129	1131	T1
O	1131	1132	)
O	1132	1133	,
O	1134	1135	8
O	1135	1136	-
O	1136	1141	weeks
O	1142	1146	post
O	1146	1147	-
O	1147	1159	intervention
O	1160	1161	(
O	1161	1163	T2
O	1163	1164	)
O	1165	1168	and
O	1169	1170	6
O	1170	1171	-
O	1171	1176	month
O	1177	1183	follow
O	1183	1184	-
O	1184	1186	up
O	1187	1188	(
O	1188	1190	T3
O	1190	1191	)
O	1191	1192	.

O	1193	1196	The
O	1197	1204	primary
O	1205	1212	outcome
O	1213	1216	was
B-outcome-Measure	1217	1220	QoL
O	1221	1229	assessed
O	1230	1234	with
O	1235	1238	the
O	1239	1243	EORT
O	1244	1247	QLQ
O	1247	1248	-
O	1248	1251	C30
O	1251	1252	.

O	1253	1262	Secondary
O	1263	1271	outcomes
O	1272	1280	included
B-outcome-Measure	1281	1286	upper
I-outcome-Measure	1286	1287	-
I-outcome-Measure	1287	1291	limb
I-outcome-Measure	1292	1305	functionality
I-outcome-Measure	1306	1309	and
I-outcome-Measure	1310	1314	body
I-outcome-Measure	1315	1326	composition
O	1326	1327	.

O	1328	1339	Statistical
O	1340	1341	(
O	1341	1348	between
O	1348	1349	-
O	1349	1354	group
O	1355	1363	analyses
O	1364	1366	of
O	1367	1377	covariance
O	1377	1378	)
O	1379	1382	and
O	1383	1391	clinical
O	1392	1399	effects
O	1400	1404	were
O	1405	1413	analyzed
O	1414	1416	by
O	1417	1426	intention
O	1427	1429	to
O	1430	1435	treat
O	1435	1436	.

O	1437	1441	Both
O	1442	1448	groups
O	1449	1455	showed
O	1456	1464	improved
O	1465	1473	outcomes
O	1473	1474	,
O	1475	1478	but
B-outcome	1479	1485	global
I-outcome	1486	1489	QoL
O	1490	1493	was
O	1494	1507	significantly
O	1508	1514	better
O	1515	1519	with
O	1520	1526	BENECA
O	1527	1534	mHealth
O	1535	1538	and
O	1539	1553	rehabilitation
O	1554	1558	than
O	1559	1565	BENECA
O	1566	1573	mHealth
O	1574	1579	alone
O	1580	1581	(
O	1581	1585	mean
O	1586	1596	difference
O	1596	1597	,
O	1598	1600	12
O	1600	1601	.
O	1601	1603	76
O	1603	1604	;
O	1605	1607	95
O	1607	1608	%
O	1609	1619	confidence
O	1620	1628	interval
O	1629	1630	4
O	1630	1631	.
O	1631	1633	85
O	1633	1634	;
O	1635	1637	20
O	1637	1638	.
O	1638	1640	67
O	1640	1641	;
O	1642	1643	P
O	1643	1644	=
O	1644	1645	0
O	1645	1646	.
O	1646	1649	004
O	1649	1650	)
O	1650	1651	,
O	1652	1656	with
O	1657	1658	a
O	1659	1667	moderate
O	1667	1668	-
O	1668	1670	to
O	1670	1671	-
O	1671	1676	large
O	1677	1683	effect
O	1684	1688	size
O	1689	1690	(
O	1690	1691	d
O	1691	1692	=
O	1692	1694	72
O	1694	1695	)
O	1695	1696	.

O	1697	1700	The
O	1701	1711	proportion
O	1712	1714	of
O	1715	1727	participants
O	1728	1737	reporting
B-outcome	1738	1746	reliable
I-outcome	1747	1755	clinical
I-outcome	1756	1767	improvement
I-outcome	1768	1770	on
I-outcome	1771	1777	global
I-outcome	1778	1781	QoL
I-outcome	1782	1784	at
I-outcome	1785	1787	T2
O	1788	1791	was
O	1792	1798	higher
O	1799	1803	with
O	1804	1810	BENECA
O	1811	1818	mHealth
O	1819	1822	and
O	1823	1837	rehabilitation
O	1838	1842	than
O	1843	1849	BENECA
O	1850	1857	mHealth
O	1858	1863	alone
O	1864	1865	(
B-iv-bin-percent	1865	1867	57
I-iv-bin-percent	1867	1868	.
I-iv-bin-percent	1868	1869	5
I-iv-bin-percent	1869	1870	%
O	1871	1873	vs
B-cv-bin-percent	1874	1876	26
I-cv-bin-percent	1876	1877	.
I-cv-bin-percent	1877	1878	3
I-cv-bin-percent	1878	1879	%
O	1879	1880	,
O	1881	1882	P
O	1882	1883	=
O	1883	1884	0
O	1884	1885	.
O	1885	1888	008
O	1888	1889	)
O	1889	1890	.

O	1891	1902	Improvement
O	1903	1905	in
B-outcome	1906	1916	subjective
I-outcome	1917	1920	and
I-outcome	1921	1930	objective
I-outcome	1931	1936	upper
I-outcome	1936	1937	-
I-outcome	1937	1941	limb
I-outcome	1942	1955	functionality
O	1956	1959	was
O	1960	1964	also
O	1965	1971	higher
O	1972	1976	with
O	1977	1983	BENECA
O	1984	1991	mHealth
O	1992	1995	and
O	1996	2010	rehabilitation
O	2010	2011	.

O	2012	2015	The
O	2016	2022	BENECA
O	2023	2030	mHealth
O	2031	2040	lifestyle
O	2041	2052	application
O	2053	2057	with
O	2058	2059	a
O	2060	2070	supervised
O	2071	2085	rehabilitation
O	2086	2093	program
O	2094	2097	had
O	2098	2099	a
O	2100	2113	statistically
O	2114	2117	and
O	2118	2128	clinically
O	2129	2140	significant
O	2141	2147	effect
O	2148	2150	on
O	2151	2154	QoL
O	2155	2158	and
O	2159	2164	upper
O	2164	2165	-
O	2165	2169	limb
O	2170	2183	functionality
O	2184	2186	in
O	2187	2193	breast
O	2194	2200	cancer
O	2201	2210	survivors
O	2211	2214	and
O	2215	2217	is
O	2218	2219	a
O	2220	2226	unique
O	2227	2230	and
O	2231	2240	important
O	2241	2250	promising
O	2251	2254	new
O	2255	2263	approach
O	2263	2264	.
